

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Anicetti Vincent R</u> (Last) (First) (Middle) COHERUS BIOSCIENCES, INC. 333 TWIN DOLPHIN DRIVE, SUITE 600 (Street) REDWOOD CA 94065 CITY CA 94065 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Coherus BioSciences, Inc. [CHRS]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) _____ Chief Operating Officer
	3. Date of Earliest Transaction (Month/Day/Year) 12/03/2020	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/03/2020		M		36,736	A	\$17.17	69,305 ⁽¹⁾	D	
Common Stock	12/03/2020		M		13,020	A	\$17.73	82,325 ⁽¹⁾	D	
Common Stock	12/03/2020		S		49,756	D	\$18.6727 ⁽²⁾	32,569 ⁽¹⁾	D	
Common Stock	12/04/2020		M		32,291	A	\$16.75	64,860 ⁽¹⁾	D	
Common Stock	12/04/2020		M		16,709	A	\$12.7	81,569 ⁽¹⁾	D	
Common Stock	12/04/2020		S		49,000	D	\$18.8509 ⁽³⁾	32,569 ⁽¹⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$17.17	12/03/2020		M			36,736	(4)	05/11/2026	Common Stock	36,736	\$0.00	0	D	
Stock Option (Right to Buy)	\$17.73	12/03/2020		M			13,020	(5)	01/10/2030	Common Stock	13,020	\$0.00	49,480	D	
Stock Option (Right to Buy)	\$16.75	12/04/2020		M			32,291	(6)	05/14/2028	Common Stock	32,291	\$0.00	17,709	D	
Stock Option (Right to Buy)	\$12.7	12/04/2020		M			16,709	(4)	08/06/2027	Common Stock	16,709	\$0.00	5,791	D	

Explanation of Responses:

- Includes 31,250 restricted stock units.
- The transaction was executed in multiple trades in prices ranging from \$18.58 to \$18.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The transaction was executed in multiple trades in prices ranging from \$18.565 to \$19.01, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- All of the shares underlying this option are vested and exercisable as of the date hereof.
- The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 10, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
- The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from May 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

/s/ Jean-Frederic Viret, as
 Attorney-in-Fact for Vincent R. 12/07/2020
 Anicetti

** Signature of Reporting Person Date

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.